Elite controllers as a model for a cure of HIV-1 infection
Elite controllers as a model for a cure of HIV-1 infection
批准号:
10269041
负责人:
Xu Yu
金额:
$86.76万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-09-23 至 2026-08-31
关键词:
AddressAgeAllogeneic Bone Marrow TransplantationAnti-Retroviral AgentsBehaviorBiological AssayBloodCCR5 geneCellsCellular AssayChIP-seqCharacteristicsChromatinComplexDNADNA MethylationDataDisease OutcomeDisease remissionEpigenetic ProcessFrequenciesGeneticGenetic TranscriptionGenomeGenomic SegmentGoalsHIVHIV-1HLA Class I GenesHematopoietic stem cellsHistonesHumanHuman GenomeImmuneImmune responseImmunologicsIndividualInfectionInterventionLeadLinkLymphoid TissueMediatingMethylationModelingMolecular ProfilingNCOA6 geneNaturePathogenicityPeripheral Blood Mononuclear CellPharmaceutical PreparationsPredispositionProvirusesRNAReportingResearchResistanceRunningSignal TransductionSiteStem cell transplantStimulusStructureStudy modelsTechniquesTechnologyTestingTimeTissuesVariantViralViral GenesViral Load resultViral reservoirViremiaVirusbasechromosomal locationclinical developmentdesignexperimental studygenome analysisgenome-widein vivoinnovationintegration siteinterestnext generation sequencingnovelpatient populationpromotervirology
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
While a sterilizing cure of HIV-1 infection has been reported in two individuals after a stem cell transplant with
CCR5∆32 homozygous cells, a spontaneous functional cure of HIV-1 occurs in 0.3-0.5% of all infected
individuals. These individuals, termed elite controllers (EC), maintain undetectable levels of HIV-1 replication in
the absence of treatment, despite the repeated isolation of replication-competent virus from viral reservoir cells.
These individuals provide living evidence that spontaneous control of HIV-1 infection is possible, and the
identification of virological and immunological mechanisms underlying such a remarkable disease outcome holds
promise for inducing a functional cure of HIV-1 infection in broader HIV-1 patient populations. Here, we propose
the novel hypothesis that undetectable viral loads in EC are related to specific genetic and epigenetic features
of proviral HIV-1 DNA in reservoir cells. Based on strong preliminary data, we posit that intact HIV-1 proviruses
from EC are preferentially located in non-genic chromosomal regions that do not permit effective viral gene
transcription, resulting in a proviral landscape in deep latency and with very limited responsiveness to
reactivation stimuli in vivo. In addition, we propose that intact proviruses from EC are also frequently integrated
into chromosomal regions that show epigenetic characteristics of repressive chromatin, evidenced by enhanced
distance to accessible chromatin and enrichment with inhibitory histone marks and hypermethylated DNA. To
investigate this, we plan to longitudinally analyze the frequency and chromosomal location of intact proviruses
in blood and lymphoid tissues of EC, using novel experimental and biocomputational analysis approaches
(Specific Aim 1). In addition, we will conduct a detailed analysis of epigenetic chromatin features at the
integration sites of intact proviruses, using next-generation sequencing assays for genome-wide characterization
of chromatin accessibility, RNA transcription, activating and inhibitory histone marks, and DNA methylation
(Specific Aim 2). Finally, we will perform functional experiments to evaluate responsiveness to viral reactivation
stimuli, using novel single-cell assays to simultaneously characterize proviral sequence, chromosomal
integration sites and HIV-1 transcriptional activity of single viral reservoir cells (Specific Aim 3); these highly
innovate single-reservoir-cell assays will allow to functionally test the hypothesis that chromosomal locations of
intact proviruses in EC maintain a state of deep latency and confer resistance to viral reactivation stimuli. If
successful, this project will significantly expand our current understanding of how natural, drug-free control is
possible, and be highly informative for inducing natural control in broader patient populations.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Elite controllers as a model for a cure of HIV-1 infection
-
批准号:10161195
-
项目类别:
-
资助金额:$88.72万
-
财政年份:2020
-
负责人:Xu Yu
-
依托单位:
Elite controllers as a model for a cure of HIV-1 infection
-
批准号:10461864
-
项目类别:
-
资助金额:$86.56万
-
财政年份:2020
-
负责人:Xu Yu
-
依托单位:
A systems biology approach to fingerprint HIV immune defense in Elite Controllers
-
批准号:9336341
-
项目类别:
-
资助金额:$82.33万
-
财政年份:2016
-
负责人:Xu Yu
-
依托单位:
A systems biology approach to fingerprint HIV immune defense in Elite Controllers
-
批准号:9204504
-
项目类别:
-
资助金额:$85.99万
-
财政年份:2016
-
负责人:Xu Yu
-
依托单位:
Targeting HIV-1 persistence with Interferon-a
-
批准号:9292717
-
项目类别:
-
资助金额:$51.3万
-
财政年份:2016
-
负责人:Xu Yu
-
依托单位:
T memory stem cell aging in HIV-1 infection
-
批准号:8650023
-
项目类别:
-
资助金额:$21.75万
-
财政年份:2014
-
负责人:Xu Yu
-
依托单位:
A systems biology approach to fingerprint HIV immune defense in Elite Controllers
-
批准号:8915895
-
项目类别:
-
资助金额:$88.56万
-
财政年份:2014
-
负责人:Xu Yu
-
依托单位:
Targeting HIV-1 persistence with Interferon-a
-
批准号:8842365
-
项目类别:
-
资助金额:$23.93万
-
财政年份:2014
-
负责人:Xu Yu
-
依托单位:
A systems biology approach to fingerprint HIV immune defense in Elite Controllers
-
批准号:8527131
-
项目类别:
-
资助金额:$72.74万
-
财政年份:2012
-
负责人:Xu Yu
-
依托单位:
A Microengraving Technology for the Study of Latently HIV-infected Primary Cells
-
批准号:8312490
-
项目类别:
-
资助金额:$40.56万
-
财政年份:2010
-
负责人:Xu Yu
-
依托单位:
A Microengraving Technology for the Study of Latently HIV-infected Primary Cells
-
批准号:8012425
-
项目类别:
-
资助金额:$42.69万
-
财政年份:2010
-
负责人:Xu Yu
-
依托单位:
Immunoregulatory Function of Myelomonocytic Receptors in HIV-1 Infection
-
批准号:8141637
-
项目类别:
-
资助金额:$15.55万
-
财政年份:2010
-
负责人:Xu Yu
-
依托单位:
A Microengraving Technology for the Study of Latently HIV-infected Primary Cells
-
批准号:8516442
-
项目类别:
-
资助金额:$38.06万
-
财政年份:2010
-
负责人:Xu Yu
-
依托单位:
A Microengraving Technology for the Study of Latently HIV-infected Primary Cells
-
批准号:8142976
-
项目类别:
-
资助金额:$40.29万
-
财政年份:2010
-
负责人:Xu Yu
-
依托单位:
Immunoregulatory Function of Myelomonocytic Receptors in HIV-1 Infection
-
批准号:7554568
-
项目类别:
-
资助金额:$44.8万
-
财政年份:2008
-
负责人:Xu Yu
-
依托单位:
Immunoregulatory Function of Myelomonocytic Receptors in HIV-1 Infection
-
批准号:7640745
-
项目类别:
-
资助金额:$44.98万
-
财政年份:2008
-
负责人:Xu Yu
-
依托单位:
Immunoregulatory Function of Myelomonocytic Receptors in HIV-1 Infection
-
批准号:8291956
-
项目类别:
-
资助金额:$43.25万
-
财政年份:2008
-
负责人:Xu Yu
-
依托单位:
Immunoregulatory Function of Myelomonocytic Receptors in HIV-1 Infection
-
批准号:7880019
-
项目类别:
-
资助金额:$43.69万
-
财政年份:2008
-
负责人:Xu Yu
-
依托单位:
Immunoregulatory Function of Myelomonocytic Receptors in HIV-1 Infection
-
批准号:8105076
-
项目类别:
-
资助金额:$43.25万
-
财政年份:2008
-
负责人:Xu Yu
-
依托单位:
Immunoregulatory Function of Myelomonocytic Receptors in HIV-1 Infection
-
批准号:8732047
-
项目类别:
-
资助金额:$43.5万
-
财政年份:2008
-
负责人:Xu Yu
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: